People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

President Donald Trump in February threatened top pharma leaders, including Eli Lilly CEO David Ricks, with tariffs unless ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Zack D Films is back at it again, but this time, he's included a gross scene at the end of his clip to highlight Ozempic side ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...